Plexus Corp. 10-Q Summary: Quarter Ended June 30, 2000
Business Context and Reporting Period
This Form 10-Q covers the three and nine months ended June 30, 2000, for Plexus Corp., a contract service provider offering design, manufacturing, and testing services to the electronics industry. The Company operates primarily in North America but recently expanded internationally through acquisitions in Mexico and the United Kingdom. The reporting period includes the impact of the SeaMED merger (accounted for as a pooling of interests) and the Agility acquisition, while the Elamex (EMS) and Keltek acquisitions were completed during or immediately after the period.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended 6/30/00 | 3 Months Ended 6/30/99 | 9 Months Ended 6/30/00 | 9 Months Ended 6/30/99 |
|---|---|---|---|---|
| Net Sales | $193,187 | $120,430 | $502,275 | $360,180 |
| Gross Profit | $28,019 | $13,714 | $71,671 | $47,446 |
| Gross Margin | 14.5% | 11.4% | 14.3% | 13.2% |
| Operating Income | $17,411 | $6,079 | $45,900 | $26,818 |
| Net Income | $10,418 | $3,726 | $28,023 | $16,815 |
| Diluted EPS | $0.53 | $0.20 | $1.46 | $0.91 |
| Cash Flow from Operations | N/A | N/A | ($7,982) | $22,033 |
| Total Debt (Current + Long-term) | $53,353 | N/A | $53,353 | N/A |
| Cash & Equivalents | $5,671 | N/A | $5,671 | N/A |
Note: Debt figures represent the sum of current portion of long-term debt ($6,460) and long-term debt ($46,893) as of June 30, 2000.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 60% year-over-year for the quarter and 39% for the nine-month period, driven by growth in networking/telecom and medical sectors and contributions from recent acquisitions.
- Profitability: Net income surged 179% for the quarter and 67% for the nine-month period. Gross margins improved significantly, partly due to the absence of a $2.2 million one-time charge related to SeaMED inventory write-downs in the prior year.
- Cash Flow Deterioration: Operating cash flow turned negative ($7.98 million used) for the nine months ended June 30, 2000, compared to $22.0 million provided in the prior year. This was primarily due to significant increases in accounts receivable ($28.7 million) and inventory ($75.2 million) to support sales growth and mitigate component shortages.
- Acquisition Activity: The Company completed the acquisition of Agility (stock), Elamex EMS operations (cash, ~$53.7 million), and Keltek (cash, debt, and stock, ~$29.4 million). These transactions significantly increased goodwill and debt levels.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates fiscal 2000 capital expenditures at approximately $50 million and fiscal 2001 at $60 million to support facility expansions and equipment purchases.
- Financing Needs: Due to increased cash needs for working capital and acquisitions, the Company expects to renegotiate and increase its credit facility size in the near term. It may also seek additional equity or debt financing.
- Margin Pressure: Gross margins are expected to decrease in the near term due to the integration of recent acquisitions (EMS and Keltek), which are expected to operate at lower margins than historical Plexus levels.
- Component Shortages: The Company faces risks from tightening markets for electronic components (e.g., memory, logic devices, PCBs), which can cause production delays and price increases. The Company has increased inventory levels to mitigate this risk.
- Customer Concentration: Sales to the ten largest customers accounted for 67% of sales for the nine months ended June 30, 2000. Lucent Technologies and General Electric were the top two customers, accounting for 24% and 11% of sales, respectively.
- Legal Contingency: The Company is a defendant in a patent infringement lawsuit filed by the Lemelson Medical, Education & Research Foundation regarding machine vision and bar-code technology. Management does not currently believe this will have a material adverse effect.
- Stock Split: A two-for-one stock split was declared on August 1, 2000, payable August 31, 2000.
Investor Verification Checklist
- Verify the sustainability of the 14.5% gross margin given the expected dilution from new international acquisitions.
- Monitor the Company's ability to secure additional credit facilities to fund the projected $60 million capital expenditure plan for fiscal 2001.
- Assess the impact of component shortages on inventory turnover, which dropped from 6.7 turns (June 1999) to 3.9 turns (June 2000).
- Track the integration progress of the Elamex (Mexico) and Keltek (UK) operations to ensure they achieve projected synergies.
- Review the status of the Lemelson patent litigation for any updates on potential licensing fees or indemnification claims.
- Confirm the timing and terms of the renegotiated credit agreement mentioned in the liquidity section.